Can Janus kinase inhibitors be used to treat immune checkpoint inhibitor associated adverse events?
Immune checkpoint inhibitors (ICI) such as cytotoxic T-lymphocyte associated protein-4 (CTLA-4), programmed cell death-1 (PD-1), programmed death ligand-1 (PD-L1), and lymphocyte activation gene-3 (LAG-3) are increasingly used to treat cancer patients since they were shown to reduce tumor progressio...
Saved in:
| Main Authors: | Jürgen Braun, Kirsten Karberg |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2024-11-01
|
| Series: | Exploration of Musculoskeletal Diseases |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/uploads/Article/A100773/100773.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report
by: Camille M. Powers, et al.
Published: (2024-12-01) -
Case Report: Immune checkpoint inhibitor-induced myositis without elevated creatine kinase
by: Klajdi Begaj, et al.
Published: (2025-06-01) -
The use of selective Janus kinase inhibitor upadacitinib in a patient with psoriatic arthritis (clinical observation)
by: Yu. A. Lushpaeva
Published: (2025-04-01) -
Efgartigimod therapy for immune checkpoint inhibitor–associated myasthenia gravis with myositis: a case report
by: Feiteng Qi, et al.
Published: (2025-07-01) -
Janus kinase inhibitors in the treatment of psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2022-02-01)